Lumigan Indian Experience
The India Lumigan Early Experience Data
(L.E.E.D.) Study Group

(Cross-references:

Introduction and Target Intra-ocular pressure - Dr. Ravin Das
The role of intra-ocular pressure in glaucoma (Landmark studies in Glaucoma) - Dr. Shabbir Hussain (Slide 1-28)
Implementing what we have learnt - Dr. Major Avinash Mishra (Slide 29-50)
Achieving the targets set by the studies & reaching difficult target pressures - Dr. Rahul Shukla (Slide 51-85)
Lumigan™ the Indian experience (L.E.E.D) - Dr. Shabbir Hussain. (Slide 86-100)

Objective and Trial Design

To evaluate the response to Bimatoprost in "real-life" clinical practices

Open-label, 2-month surveillance trial
- In glaucoma or ocular hypertension patients who need additional IOP lowering, or who are intolerant of other medications
- Bimatoprost was used as monotherapy, replacement therapy or adjunctive therapy at physicians' discretion

Patient Population

571 patients from 72 clinical sites in India
6.4 % lost to follow-up
74.2 % equal to or older than 50
38.5 % female and 61.5 % Male
97.6 % Asian
90.2% with open-angle glaucoma and 9.8% with ocular hypertension

Baseline Characteristics

Medications at Baseline and During Study

Adverse Events